10 June 2020
Visiongain has launched a new report Liquid Biopsy Market Report 2020-2030: Forecasts by Product (Instruments, Kits & Reagents, Services), by Sample Type (Blood Samples, Urine Samples, Others), by Biomarker (Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Others), by Cancer Type (Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Others), by End-user (Hospitals, Diagnostic Laboratories, Academic Institutions, Cancer Research Centres), by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa), Plus Analysis of Leading Companies.
Liquid biopsy market is driven by its advantages over conventional methods of solid tissue biopsy such as, ease of use and non-invasive method to access molecular information about the tumor genome. Moreover, liquid biopsy tests facilitate early detection of cancer recurrence, and characterisation of tumor dynamics. Furthermore, safety and efficiency of cancer treatment is improved by the use of these tests, owing to their ability to characterise the new lesions, implement apt therapeutic targets, and predict the treatment outcome.
Moreover, increasing disposable income among cancer patients, surge in prevalence of cancer cases, and rising patient preference for minimally invasive therapies are anticipated to fuel the market growth. Rise in healthcare expenditure in developing countries, such as India and China, and use of liquid biopsy tests to treat rare cancers are expected to present multiple opportunities for market growth. However, this growth is restricted, owing to the presence of alternatives to liquid biopsies and unclear reimbursement and regulatory scenario.
Over the last few years, the global market players in the liquid biopsy field are emphasising their research in oncogenic mutation detecting tests using biological fluids (such as blood, urine, and other). In addition, growing number of product launches is supporting the growth of liquid biopsy market. For instance, in March 2016, MDxHealth SA. (Belgium) launched its molecular diagnostic product, SelectMDx in the United States. SelectMDx is used to diagnose prostate cancer using a liquid biopsy method on a urine sample to indicate the probability that a biopsy will find cancer. This can aid the healthcare professional to decide whether there is the need for a full prostate biopsy or not, potentially reducing the number of unnecessary biopsies performed.
Similarly, in September 2015, Roche Holdings AG (Switzerland) launched its molecular diagnostic product, namely, cobas EGFR Mutation Test v2 in European countries accepting CE marked products. The cobas EGFR Mutation Test v2 involves the analysis of plasma or tumour tissue sample to detect Non-Small Cell Lung Cancer (NSCLC). This product identifies around 42 mutations in the Epidermal Growth Factor Receptor (EGFR) gene. This product provides an opportunity to analyse cancer mutations. Furthermore, cobas EGFR Mutation Test v2 was approved by the U.S. FDA for the diagnosis of non-small lung cancer (NSCLC). Likewise, in Mar 2017, Myriad Genetics, Inc. launched EndoPredict test for the diagnosis of early-stage breast cancer. This test was launched in the US and can be used to assess 10-year risk of disease recurrence.
In addition, growing number of biotechnology companies focusing on liquid biopsy is further driving the growth of liquid biopsy market. Companies such as Guardant Health, Inc. (US) are focusing on the development of comprehensive liquid biopsy platforms. On Feb 2018, their product Guardant360 assay received an Expedited Access Pathway (EAP) designation from USFDA.
Widely used cancer detecting platforms include Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS). These two platforms detect biomarkers across cancer indications such as lung cancer, prostate cancer, breast cancer and others, using tissue or other samples from the patient.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.